David Greenfield Human Physiology Unit
Nottingham, Notts, NG72UH, United Kingdom
NCT Number: NCT03439917
It will be evaluated whether carnitine, a dietary supplement, reduces liver fat and improves metabolism in individuals who have a high concentration of fat within their liver. Participants will be given either Carnitine or placebo, together with a meal replacement milkshake twice daily for 6 months.
Looking for future studies?
Notify Me18 year–50 year
Male
Interventional
Not applicable
Nottingham, Notts, NG72UH, United Kingdom
NAFLD occurs when too much fat accumulates in liver tissue. This can, over time, cause inflammation and scarring of the liver, eventually leading to chronic liver disease and cirrhosis. It is strongly associated with diabetes and obesity, both of which are endemic in Western societies.
Carnitine enables cells in the body to use fat as a fuel, and recent studies have suggested that carnitine supplementation may reduce liver triglyceride content. Muscle and liver are the major sites in the body which coordinate glucose and fat metabolism. As well as assessing the effect of carnitine supplementation on liver fat, its effect on metabolic processes within these tissues will also be measured
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
2g L-Carnitine tartrate as a powder consumed twice a day
325ml dairy-based meal replacement drink ('Slimfast' trademark of KSF Acquisition UK Ltd) consumed twice a day
Other names: Slimfast
2g Maltodextrin powder packaged to mimic carnitine powder consumed twice a day
Time frame: 24 weeks
IHTG measured by proton magnetic resonance spectroscopy
Time frame: 24 weeks
suppression of glucose output from the liver during a 20 mU.m-2.min-1 hyperinsulinaemic euglycaemic clamp
Time frame: 24 weeks
whole body glucose uptake during a 50 mU.m-2.min-1 hyperinsulinaemic euglycaemic clamp
Time frame: 24 weeks
lipid content of the vastus lateralis muscle measured by proton magnetic resonance spectroscopy
Time frame: 24 weeks
Arterialised-venous vs. femoral venous difference in blood glucose concentration during the last hour of a 2 hour 50 mU.m-2.min-1 hyperinsulinaemic euglycaemic clamp
Time frame: 24 weeks
Fat and lean tissue mass assessment by dual energy X-ray absorptiometry
Time frame: 24 weeks
hepatic ATP flux assessed by 31-phosphorous magnetic resonance spectroscopy
University of Nottingham
Other
Effect of Carnitine Supplementation on Liver Steatosis, Insulin Sensitivity, Plasma Glucose Homeostasis, Skeletal Muscle Metabolism and Energetics: a Pilot Study
Acronym: ECLIPSE
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05724134
Body Weight, Diabetes Mellitus
New York, United States
View Trial DetailsNCT05729282
Diabetes Mellitus, Digestive System Diseases
New York, United States
View Trial DetailsNCT04342390
Body Weight, Childhood Obesity
Little Rock, Arkansas, United States
View Trial DetailsNCT04117802
Bacteremia, Body Weight
Québec, Canada
View Trial Details